IgA Nephropathy Overview

IgA nephropathy (IgAN), or Berger’s disease, is the most common primary glomerular disease that can progress to end stage renal failure (ESRD). Because of the critical interaction between an intrinsic antigen (galactose-deficient IgA1) and circulating anti-glycan antibodies, IgA nephropathy can be considered an autoimmune disease.

“IgA Nephropathy Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the IgA Nephropathy Market.

The IgA Nephropathy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the IgA Nephropathy Pipeline Report:

• Companies across the globe are diligently working toward developing novel IgA Nephropathy treatment therapies with a considerable amount of success over the years. IgA Nephropathy Key players such as – IgA proteases Selecta Biosciences, Shanghai Alebund Pharmaceuticals, Rohto Pharmaceutical, Guangdong Hengrui Pharmaceutical, Eledon Pharmaceuticals, Ionis Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Visterra, Chinook Therapeutics, Novartis Pharmaceuticals, and others, are developing therapies for the IgA Nephropathy treatment 

• IgA Nephropathy Emerging therapies such as – Research programme, AP 305, ADR-001, SHR 2010, AT-1501, IONIS FB LRx, HR19042, Sibeprenlimab, Atrasentan, LNP023, and others are expected to have a significant impact on the IgA Nephropathy market in the coming years.   
• In November 2021, the European Medicines Agency (EMA) granted orphan drug designation to the investigational drug avacopan for the treatment of IgA nephropathy.
• In September 2021, the FDA granted fast track designation to the investigational drug ANG-3777 for the treatment of IgA nephropathy.
• In July 2021, a phase IIb clinical trial evaluating the efficacy and safety of the investigational drug sparsentan in the treatment of IgA nephropathy met its primary endpoint, demonstrating significant reduction in proteinuria compared to irbesartan alone.

Route of Administration

IgA Nephropathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravenous 
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides 
• Polymer 
• Small molecule
• Gene therapy

IgA Nephropathy Pipeline Therapeutics Assessment

• IgA Nephropathy Assessment by Product Type
• IgA Nephropathy By Stage and Product Type
• IgA Nephropathy Assessment by Route of Administration
• IgA Nephropathy By Stage and Route of Administration
• IgA Nephropathy Assessment by Molecule Type
• IgA Nephropathy by Stage and Molecule Type

DelveInsight’s IgA Nephropathy Report covers around 30+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Some of the key companies in the IgA Nephropathy Therapeutics Market include:

Key companies developing therapies for IgA Nephropathy treatment are – Chinook Therapeutics, Inc., RemeGen Co., Ltd., Novartis, Jiangsu HengRui Medicine Co., Ltd., Ionis Pharmaceuticals, Inc., Vera Therapeutics, Inc., Eledon Pharmaceuticals, Guangdong Hengrui Pharmaceutical Co., Ltd, Omeros Corporation, Otsuka Pharmaceutical, Alnylam Pharmaceuticals, MorphoSys AG, Rohto Pharmaceutical, Alexion Pharmaceuticals, Apellis Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Takeda, Travere Therapeutics, BioCryst Pharmaceuticals, Transcenta Holding, Shanghai Alebund Pharmaceuticals, DiaMedica Therapeutics, SELECTA BIOSCIENCES, Kira Pharmaceuticals, Alpine Immune Sciences, and others

Emerging IgA Nephropathy Drugs Under Different Phases of Clinical Development Include:

• Research programme: IgA proteases Selecta Biosciences
• AP 305: Shanghai Alebund Pharmaceuticals
• ADR-001: Rohto Pharmaceutical
• SHR 2010: Guangdong Hengrui Pharmaceutical
• AT-1501: Eledon Pharmaceuticals
• IONIS FB LRx: Ionis Pharmaceuticals
• HR19042: Jiangsu HengRui Medicine Co., Ltd.
• Sibeprenlimab: Visterra
• Atrasentan: Chinook Therapeutics
• LNP023: Novartis Pharmaceuticals

Get a Free Sample PDF Report to know more about IgA Nephropathy Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/iga-nephropathy-igan-pipeline-insight

IgA Nephropathy Pipeline Analysis:

The IgA Nephropathy pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of IgA Nephropathy with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for IgA Nephropathy Treatment.
• IgA Nephropathy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• IgA Nephropathy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the IgA Nephropathy market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further IgA Nephropathy product details are provided in the report. Download the IgA Nephropathy pipeline report to learn more about the emerging IgA Nephropathy therapies

IgA Nephropathy Pipeline Market Drivers

• Increase in prevalence of IgA Nephropathy (IgAN)
• Increment in the number of government initiatives to spread awareness

IgA Nephropathy Pipeline Market Barriers

• Lack of in-depth understanding of the disease pathogenesis
• The unreported and undiagnosed IgA Nephropathy cases

Scope of IgA Nephropathy Pipeline Drug Insight    

• Coverage: Global
• Key IgA Nephropathy Companies: IgA proteases Selecta Biosciences, Shanghai Alebund Pharmaceuticals, Rohto Pharmaceutical, Guangdong Hengrui Pharmaceutical, Eledon Pharmaceuticals, Ionis Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Visterra, Chinook Therapeutics, Novartis Pharmaceuticals, and others
• Key IgA Nephropathy Therapies: Research programme, AP 305, ADR-001, SHR 2010, AT-1501, IONIS FB LRx, HR19042, Sibeprenlimab, Atrasentan, LNP023, and others
• IgA Nephropathy Therapeutic Assessment: IgA Nephropathy current marketed and IgA Nephropathy emerging therapies
• IgA Nephropathy Market Dynamics: IgA Nephropathy market drivers and IgA Nephropathy market barriers 

Request for Sample PDF Report for IgA Nephropathy Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report to know more about IgA Nephropathy drugs and therapies

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432, Las Vegas NV
City: Las Vegas
State: United States
Country: United States
Website: https://www.delveinsight.com